Sofia Lampaki

Summary

Affiliation: Aristotle University of Thessaloniki
Country: Greece

Publications

  1. ncbi Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Gynecol Oncol 115:97-101. 2009
  2. ncbi Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
  3. ncbi Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study
    Evangelia Razis
    1st Department of Medical Oncology, Hygeia Hospital, Athens, Greece
    BMC Cancer 8:234. 2008
  4. ncbi Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
    Aristotle Bamias
    Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece
    BMC Cancer 6:228. 2006
  5. ncbi Rare mutations predisposing to familial adenomatous polyposis in Greek FAP patients
    Markos Mihalatos
    Molecular Biology Research Center HYGEIA Antonis Papayiannist, Athens, Greece
    BMC Cancer 5:40. 2005
  6. ncbi Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
    Aristotelis Bamias
    Department of Clinical Therapeutics, Athens University, Medical School, Athens, Greece
    BMC Cancer 10:45. 2010
  7. ncbi Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
    Vasilis Karavasilis
    Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 5:25. 2005
  8. ncbi Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
    G Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Ann Oncol 19:853-60. 2008
  9. ncbi Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation
    George Fountzilas
    Department of Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Anticancer Res 26:4675-86. 2006
  10. ncbi Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group
    G Fountzilas
    Aristotle University of Thessaloniki Medical School, Thessaloniki, Macedonia, Greece
    J Clin Oncol 19:2232-9. 2001

Detail Information

Publications119 found, 100 shown here

  1. ncbi Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Gynecol Oncol 115:97-101. 2009
    ....
  2. ncbi Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
    ..Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity...
  3. ncbi Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study
    Evangelia Razis
    1st Department of Medical Oncology, Hygeia Hospital, Athens, Greece
    BMC Cancer 8:234. 2008
    ..The aim of this study was to explore EGFR and the downstream effector phosphatase and tensin homologue deleted on chromosome 10 (PTEN) as potential predictors of response to cetuximab...
  4. ncbi Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
    Aristotle Bamias
    Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece
    BMC Cancer 6:228. 2006
    ..Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10-50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma...
  5. ncbi Rare mutations predisposing to familial adenomatous polyposis in Greek FAP patients
    Markos Mihalatos
    Molecular Biology Research Center HYGEIA Antonis Papayiannist, Athens, Greece
    BMC Cancer 5:40. 2005
    ..The vast majority of APC mutations are point mutations or small insertions/deletions which lead to truncated protein products. Splicing mutations or gross genomic rearrangements are less common inactivating events of the APC gene...
  6. ncbi Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
    Aristotelis Bamias
    Department of Clinical Therapeutics, Athens University, Medical School, Athens, Greece
    BMC Cancer 10:45. 2010
    ..We studied the prognostic significance of baseline characteristics and we compared the risk stratification with the established Memorial Sloan Kettering Cancer Center (MSKCC) model...
  7. ncbi Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
    Vasilis Karavasilis
    Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 5:25. 2005
    ..We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets...
  8. ncbi Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
    G Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Ann Oncol 19:853-60. 2008
    ..A randomized phase III trial in high-risk breast cancer patients was conducted, to further explore the impact of dose-density in the adjuvant treatment for breast cancer. The safety analysis is presented...
  9. ncbi Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation
    George Fountzilas
    Department of Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Anticancer Res 26:4675-86. 2006
    ..Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown...
  10. ncbi Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group
    G Fountzilas
    Aristotle University of Thessaloniki Medical School, Thessaloniki, Macedonia, Greece
    J Clin Oncol 19:2232-9. 2001
    ..To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC)...
  11. ncbi Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group
    George Fountzilas
    1st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    Clin Breast Cancer 4:120-5. 2003
    ..9+). In conclusion, this retrospective analysis suggests that continuation of trastuzumab beyond disease progression in patients with HER2-overexpressing metastatic breast cancer is feasible and safe. Randomized studies are warranted...
  12. ncbi Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
    G Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Macedonia, Greece
    Ann Oncol 17:1560-7. 2006
    ..In the present randomized phase III trial we compared two new combinations containing new drugs with proven activity in phase II studies with patients with HNC...
  13. ncbi Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
    G Fountzilas
    Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Ann Oncol 16:1762-71. 2005
    ....
  14. ncbi Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study
    George Fountzilas
    Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Med Oncol 22:269-79. 2005
    ..CCRT should remain standard treatment for patients with LA-HNC. Novel induction combinations, such as that reported in the present study, should be evaluated in combination with CCRT only in the context of clinical trials...
  15. ncbi Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group
    George Fountzilas
    AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Nea Efkarpia, 56249 Thessaloniki, Greece
    Breast Cancer Res Treat 92:1-9. 2005
    ..7 and 42.7%, respectively), with the majority (72.1%) negative for cytoplasmic p27(kipl). The observed efficacy data in this study were similar to those reported for the combination of paclitaxel and carboplatin alone...
  16. ncbi Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study
    George Fountzilas
    AHEPA Hospital, Aristotle, University of Thessaloniki, Thessaloniki, Greece
    Strahlenther Onkol 181:223-30. 2005
    ..Clinical research on the treatment of nasopharyngeal cancer (NPC) has been focused primarily on the reduction of incidence of the development of distant metastases as well as the improvement of locoregional control...
  17. ncbi Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study
    George Fountzilas
    AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Med Oncol 21:95-107. 2004
    ..The present study clearly demonstrated that concomitant chemoradiotherapy with platinum analogs significantly prolongs 3-yr survival and median OS in patients with locally advanced HNC compared to conventional RT alone...
  18. ncbi Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study
    G Fountzilas
    First Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Macedonia, Greece
    Ann Oncol 12:1545-51. 2001
    ..To evaluate the activity and acute toxicity of the combination of weekly paclitaxel as first-line chemotherapy and trastuzumab, in patients with HER-2/neu overexpressing advanced breast cancer (ABC)...
  19. ncbi Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
    G Fountzilas
    Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Ann Oncol 15:1517-26. 2004
    ..To compare survival between patients with advanced breast cancer (ABC) treated with epirubicin/paclitaxel (Taxol) or paclitaxel/carboplatin (Cp) chemotherapy...
  20. ncbi Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
    G Fountzilas
    AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    Oncology 60:214-20. 2001
    ..The E-T-CMF regimen is well tolerated, as adjuvant treatment, in patients with operable breast cancer with promising activity and deserves further evaluation in phase III studies...
  21. ncbi A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study
    G Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Macedonia, Greece
    Breast Cancer Res Treat 115:87-99. 2009
    ..Effective anthracycline-free combinations need to be evaluated in metastatic breast cancer (MBC), due to the increased number of patients treated with anthracycline-based adjuvant chemotherapy...
  22. ncbi Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Anticancer Res 29:529-38. 2009
    ..Induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) has the potential of being an ideal multi-modality approach for improving the prognosis of patients with squamous cell carcinoma of the head and neck (SSCHN)...
  23. ncbi Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Cancer Invest 26:784-93. 2008
    ..The 6-month progression-free survival (PFS) was 30%. Median PFS was 4.1 months and median survival 7.3 months with a 1 year survival rate of 27%. The above combination demonstrated promising activity in advanced pancreatic cancer...
  24. ncbi Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
    G Fountzilas
    1st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece
    Oncology 58:227-36. 2000
    ..Furthermore, a meta-analysis suggested that the combination of FU with LV increased the response rate as compared to FU monotherapy in patients with advanced colorectal cancer...
  25. ncbi Accelerated bifractionated radiation with concurrent cisplatin administration in locally advanced head and neck cancer: a feasibility study
    G Fountzilas
    AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    Tumori 83:735-9. 1997
    ..CONCLUSIONS: Accelerated twice-daily radiation with concurrent cisplatin is effective in locally advanced head and neck cancer and can be safely given with manageable toxicity...
  26. ncbi Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study
    G Fountzilas
    Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece
    Tumori 77:426-31. 1991
    ....
  27. ncbi Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
    D Bafaloukos
    Department of Medical Oncology, Metropolitan Hospital, Ethnarhou Makariou Street, No 9, N Faliro, Athens 18547, Greece
    Br J Cancer 91:1639-44. 2004
    ..There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and well-tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS...
  28. ncbi Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group
    D Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece
    Lung Cancer 58:355-61. 2007
    ..The purpose of this study was to evaluate the efficacy and toxicity of cisplatin, etoposide and irinotecan as first-line treatment in patients with extensive small-cell lung cancer (E-SCLC)...
  29. ncbi Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study
    G Fountzilas
    AHEPA Hospital, Aristotle University, Thessaloniki, Macedonia, Greece
    Tumori 81:354-8. 1995
    ..CONCLUSIONS: Radiation and concurrent administration of carboplatin determined a high CR rate in patients with HNC, although the superiority of this combined modality approach over radiation alone has to be proven in phase III trials...
  30. ncbi Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
    P A Kosmidis
    Department of Medical Oncology, Hygeia Hospital, Athens, Greece
    Ann Oncol 19:115-22. 2008
    ..This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer...
  31. ncbi Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)
    P A Kosmidis
    Department of Medical Oncology, Hygeia Hospital, Athens, Greece
    Ann Oncol 22:827-34. 2011
    ..This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer...
  32. ncbi Platinum-based induction chemotherapy followed by radiation as definitive treatment for patients with locally advanced cancer of the oral cavity, oropharynx and hypopharynx. A retrospective analysis of 32 cases
    G Fountzilas
    Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece
    J Chemother 3:183-8. 1991
    ..In conclusion, induction chemotherapy followed by radiation therapy may omit radical surgery, without compromising survival, in some patients with locally advanced cancer of the oral cavity, oropharynx and hypopharynx...
  33. ncbi Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    Anticancer Res 29:745-51. 2009
    ..The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC)...
  34. ncbi Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases
    G Fountzilas
    Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece
    Acta Oncol 30:831-4. 1991
    ..5 months. In conclusion, induction chemotherapy with a platinum-based regimen followed by radiation therapy achieved a high rate of local control. If the treatment also prolongs survival must, however, be studied by randomized trials...
  35. ncbi Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
    V Malamou-Mitsi
    Department of Pathology, School of Medicine, University of Ioannina, Ioannina, Greece
    Ann Oncol 17:1504-11. 2006
    ..To assess the prognostic and predictive significance of p53 and Bcl-2 protein expression in high risk patients with breast cancer treated with dose-dense sequential chemotherapy...
  36. ncbi Carboplatin and paclitaxel in advanced or metastatic endometrial cancer
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Gynecol Oncol 109:250-4. 2008
    ..The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent endometrial carcinoma...
  37. ncbi Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Onco
    G Fountzilas
    Aristotle University of Thessaloniki Medical School, Greece
    Ann Oncol 10:671-6. 1999
    ..However, this difference in response rate did not translate into a survival benefit...
  38. ncbi Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic Co-operative Oncology Group study
    G Fountzilas
    AHEPA Hospital, Thessaloniki, Macedonia, Greece
    Acta Oncol 33:825-30. 1994
    ..Median relapse-free survival has not yet been reached. Combined radiation therapy and cisplatin appears to be a highly active treatment in patients with advanced head and neck cancer as far as primary locoregional response is concerned...
  39. ncbi Does substitution of surgery with induction chemotherapy preserve organ function in inoperable head and neck cancer? A retrospective analysis of 73 cases
    G Fountzilas
    AHEPA Hospital, Aristotle University, Thessaloniki, Macedonia, Greece
    J Chemother 6:272-8. 1994
    ....
  40. ncbi Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group
    A Bamias
    Department of Clinical TherapeuticsUniversity of Athens, School of Medicine, Athens, Greece
    J Clin Oncol 22:2150-4. 2004
    ..We prospectively studied a cohort of patients who underwent surgery for high-risk carcinoma of the upper urinary tract to assess the feasibility of the combination of paclitaxel and carboplatin as adjuvant treatment...
  41. ncbi Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience
    D Pectasides
    Second Department of Internal Medicine, Oncology Section, University General Hospital Attikon, Athens, Greece
    Int J Gynecol Cancer 17:1003-10. 2007
    ..001). In conclusion, younger women with EOC have significantly improved survival compared to older patients. Age, PS, stage of the disease at diagnosis, and residual disease are important independent predictors for survival...
  42. ncbi Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study
    E Briasoulis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Anticancer Drugs 15:747-52. 2004
    ..The low hematological toxicity and modest activity observed leave questions concerning the optimal timing of this combination...
  43. ncbi A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Athens, Greece
    Anticancer Res 27:4411-7. 2007
    ..The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients...
  44. ncbi Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Med Oncol 23:147-60. 2006
    ..Paclitaxel coupled with carboplatin provides an alternative therapeutic option for anthracycline-exposed patients and warrants further clinical research in the direction of anthracycline-free management of metastatic breast cancer...
  45. ncbi G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting
    E Briasoulis
    Department of Medical Oncology, University of Ioannina, Ioannina, Greece
    Cancer 91:909-17. 2001
    ..Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients...
  46. ncbi Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines
    G Fountzilas
    AHEPA Hospital, Aristotle University, Thessaloniki, Macedonia, Greece
    Tumori 79:389-92. 1993
    ..CONCLUSIONS: The combination of carboplatin and oral etoposide is effective and should probably be considered as an alternative therapeutic option for patients with advanced breast cancer refractory to anthracyclines...
  47. ncbi High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study
    G Fountzilas
    AHEPA University Hospital, Thessaloniki, Greece
    Tumori 77:232-6. 1991
    ..Monotherapy with high doses of epirubicin has definite activity in advanced breast cancer and deserves further study in combination with hematopoietic growth factors which might allow a higher dose intensity...
  48. ncbi Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients
    Eleni Timotheadou
    Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Greece
    Anticancer Res 27:4481-9. 2007
    ..Identification of molecular prognostic and predictive markers remains under investigation with results that are often conflicting...
  49. ncbi Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience
    Dimitrios Pectasides
    Oncology Section, 2nd Department of Internal Medicine Propaedeutic, University of Athens Medical School, Attikon University Hospital, 1 Rimini Street, Haidari, Gravias 5B, Aghia Paraskevi, Athens 15342, Greece
    Gynecol Oncol 102:285-91. 2006
    ..This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC)...
  50. ncbi Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Anticancer Res 29:737-44. 2009
    ..Various prognostic factors have been investigated in order to predict the minority of male germ cell tumor (GCT) patients who will develop resistant disease. However, no prognostic system has been proven accurate...
  51. ncbi Serum concentrations of soluble ICAM-1 and VCAM-1 in patients with colorectal cancer. Clinical implications
    K Giannoulis
    3rd Department of Surgery, AHEPA University Hospital, Thessaloniki, Greece
    Tech Coloproctol 8:s65-7. 2004
    ..In colorectal cancer (CRC), serum levels of adhesion molecules ICAM-1 and VCAM-1 increase with progressing disease. Our aim was to investigate the effect of treatment in serum ICAM-1 and VCAM-1...
  52. ncbi Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    D Pectasides
    Second Department of Internal Medicine, Propaeduetic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Anticancer Res 28:1421-7. 2008
    ..Granulosa cell tumors (GCT) are rare malignant neoplasms of the ovaries with, usually, indolent biological behavior...
  53. ncbi Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study
    Evangelos Briasoulis
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Anticancer Drugs 21:785-9. 2010
    ..At the recommended doses this is a well-tolerated regimen with noticeable antitumor activity and warrants further investigation in phase II studies...
  54. ncbi Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)
    George Fountzilas
    1 st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Cancer Invest 22:655-62. 2004
    ..This combination is the first to demonstrate a survival advantage in this group of patients. To improve on these results, we investigated a triplet, paclitaxel-gemcitabine-trastuzumab (TGH), in a phase II study...
  55. ncbi The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models
    Georgios Iliadis
    Department of Radiation Oncology, Papageorgiou General Hospital, Thessaloniki, Greece
    Strahlenther Onkol 185:743-50. 2009
    ....
  56. ncbi Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy
    G Pentheroudakis
    Department of Medical Oncology, Medical School, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Cancer Chemother Pharmacol 60:733-9. 2007
    ..In this phase I study, we investigated an alternative, dose-intense continuous regimen...
  57. ncbi A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Neoplasma 57:47-54. 2010
    ..Keywords: KiSS1, metastasis-suppressor gene, breast cancer, mutation, transcription...
  58. ncbi Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Panepistimiou Avenue, 45110 Ioannina, Greece
    Lung Cancer 45:349-55. 2004
    ....
  59. ncbi Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Breast Cancer Res Treat 116:131-43. 2009
    ..We sought to study the predictive significance and correlations of transcriptional profiling of the ER, PgR and microtubule-associated protein Tau (MAP-Tau) genes in early breast cancer...
  60. ncbi Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study
    George Fountzilas
    1st Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki-Macedonia, Greece
    Am J Clin Oncol 27:57-67. 2004
    ..Similarly, six cycles of CNF preceding 5 years of tamoxifen did not translate to a 15% RFS benefit in node-positive postmenopausal patients...
  61. ncbi Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG)
    Eleni Timotheadou
    Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Tumori 91:309-13. 2005
    ..Further research is warranted for the development of more effective and less toxic regimens in this setting...
  62. ncbi Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Gravias 5B, Aghia Paraskevi, 153 42 Athens, Greece
    Gynecol Oncol 97:436-41. 2005
    ..This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stages III and IV mEOC and serous EOC (sEOC)...
  63. ncbi Carboplatin and paclitaxel in metastatic or recurrent cervical cancer
    Dimitrios Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Athens, Greece
    Int J Gynecol Cancer 19:777-81. 2009
    ..The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent carcinoma of the cervix...
  64. ncbi Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer
    E Andreopoulou
    Department of Medical Oncology, University of Ioannina, Greece
    Anticancer Res 22:1903-8. 2002
    ..Initial tumor volume has prognostic significance only for the time to progression, whereas residual tumor volume has for both time to progression and survival...
  65. ncbi Serum levels of bcl-2 in patients with colorectal cancer
    K Giannoulis
    1 Alexandrou Svolou, 546 22 Thessaloniki, Greece
    Tech Coloproctol 8:s56-8. 2004
    ..Our aim was to investigate the presence of bcl-2 protein in the serum and to examine the association between its levels, stage and tumour load, in patients with CRC...
  66. ncbi [Combined radiochemotherapy in locally advanced nasopharyngeal carcinoma]
    J Daniilidis
    Hals Nasen Ohren Klinik, Aristoteles Universität Thessaloniki, Klinikum AHEPA, 54006 Thessaloniki Griechenland
    HNO 49:732-8. 2001
    ..Nasopharyngeal cancer (NPC) is a tumor of epidermoid origin with an entirely different biological behavior than other carcinoma of the head and neck region...
  67. ncbi Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Med Oncol 23:479-88. 2006
    ..Infection developed in nine patients. Two cases of febrile neutropenia were reported. The E-CMF-doc regimen, as used in this study, is feasible and well tolerated. Its impact on survival should be evaluated in phase III trials...
  68. ncbi Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics
    Vassiliki Kotoula
    Department of Pathology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
    PLoS ONE 4:e7746. 2009
    ..In routine diagnostics, however, suboptimal templates pose the challenge. Herein, we addressed the applicability of sequencing and two Q-PCR methods on prospectively assessed diagnostic cases for KRAS mutations...
  69. ncbi A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, 564 03, Thessaloniki, Macedonia, Greece
    Cancer Chemother Pharmacol 65:649-60. 2010
    ..Angiogenesis is an important biological process in SCCHN. We, therefore, evaluated the activity and safety of sunitinib, an oral tyrosine kinase inhibitor that targets multiple receptors, in patients with RM-SCCHN...
  70. ncbi Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region
    Amanda Psyrri
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Med Oncol 23:1-15. 2006
    ..Cyclin-dependent kinases, the tumor suppressor p53 gene, and epidermal growth factor receptor are some of the molecular targets of such therapies in patients with SCCHN...
  71. ncbi A novel chromatographic method for Ep-CAM mRNA detection in peripheral blood and bone marrow of patients with metastatic colorectal cancer
    Charisios Karanikiotis
    Department of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece
    Anticancer Res 25:319-23. 2005
    ....
  72. ncbi Clinical and molecular prognostic factors in operable laryngeal cancer
    Konstantinos Vlachtsis
    Department of Otorhinolaryngology Head and Neck Surgery, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    Eur Arch Otorhinolaryngol 262:890-8. 2005
    ..These markers, apart from their role in carcinogenesis, seem to play an important role in tumor relapse...
  73. ncbi Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
    Ioannis Kostopoulos
    Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
    Breast Cancer Res Treat 96:251-61. 2006
    ..No predictive ability of HER-2 status or VEGF overexpression for T treatment was evident...
  74. ncbi The role of interferons in the treatment of colorectal cancer
    G Fountzilas
    1st Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloniki, Macedonia, Greece
    J Chemother 5:271-7. 1993
    ..In conclusion, the role of IFNs in the treatment of colorectal cancer has not been defined yet. It is hoped that phase III trials which currently are in progress will clarify this issue...
  75. ncbi Merkel cell carcinoma of the skin: a retrospective study of 24 cases by the Hellenic Cooperative Oncology Group
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Oncology 72:211-8. 2007
    ..The purpose of this retrospective study was to present the epidemiological and clinical characteristics of 24 patients with Merkel cell carcinoma of the skin (MCC) and their response to various therapeutic modalities...
  76. ncbi Retinoids in the management of head and neck cancer. An update
    G Fountzilas
    1st Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloniki, Macedonia, Greece
    J Chemother 6:127-38. 1994
    ....
  77. ncbi Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece
    J Clin Oncol 27:939-44. 2009
    ....
  78. ncbi Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Crit Rev Oncol Hematol 66:237-47. 2008
    ..We sought to present epidemiology, management and outcome data on fit elderly patients with common metastatic cancers and to identify predictors of clinical benefit from palliative chemotherapy...
  79. ncbi Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature
    George Lazaridis
    Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Cancer Treat Rev 34:693-700. 2008
    ..Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis. We retrospectively analysed their management and outcome and performed a systematic review of CUPL series published in the literature...
  80. ncbi HLA Class II alleles and the presence of circulating Epstein-Barr virus DNA in Greek patients with nasopharyngeal carcinoma
    Charisios Karanikiotis
    424 Army General Hospital, Thessaloniki, Greece
    Strahlenther Onkol 184:325-31. 2008
    ....
  81. ncbi Prognostic factors and significance of the revised 6th edition of the AJCC classification in patients with locally advanced nasopharyngeal carcinoma
    Anna Kalogera-Fountzila
    Department of Radiology, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Strahlenther Onkol 182:458-66. 2006
    ..The degree of tumor extension into the parapharyngeal space should be considered in future TNM staging revisions...
  82. ncbi Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
    Ioannis Kostopoulos
    Department of Medical Oncology Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 9:339. 2009
    ..We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome...
  83. ncbi The prevalence of hepatitis C and hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a Hellenic Cooperative Oncology Group Study
    E Giannoulis
    AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Acta Haematol 112:189-93. 2004
    ..The increased prevalence of HGV infection detected in patients with NHL could imply the potential participation of HGV in the pathogenesis of NHL...
  84. ncbi The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group
    Aristotle Bamias
    Department of Clinical Therapeutics, Athens University, School of Medicine, Athens, Greece
    Cancer 106:297-303. 2006
    ..The objective of the current multicenter Phase II study was to evaluate the safety and efficacy of the combination of gemcitabine and carboplatin as first-line treatment in unselected patients with advanced urothelial carcinoma...
  85. ncbi Elderly patients with squamous lung carcinoma: faring better or worse?
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, 45500 Ioannina, Greece
    Support Care Cancer 14:867-70. 2006
    ..The clinical course, management, and outcome of squamous lung cancer in the elderly have not been thoroughly studied to date...
  86. ncbi Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Haidari, Athens, Greece
    Anticancer Res 25:3553-8. 2005
    ..A retrospective study of all patients diagnosed with brain metastases from EOC over the last 20 years, according to the Hellenic Cooperative Oncology Group (HeCOG) tumor registry, was conducted...
  87. ncbi Technology evaluation: TriGem, Titan
    Evangelia Razis
    First Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Thessaloniki, Macedonia, Greece
    Curr Opin Mol Ther 5:204-7. 2003
    ..Phase II trials of TriGem for use in advanced melanoma were ongoing by June 2002. TriGem also has potential for the treatment of psoriasis, for which phase II trials had begun by 1996...
  88. ncbi Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer
    Evangelia Razis
    1st Department of Medical Oncology, Hygeia Hospital, 4 Erithrou Stavrou and Kifissias Av, 151 23 Athens, Greece
    Cancer Invest 22:10-5. 2004
    ..We conducted a multi-institutional phase II study to assess the activity of the combination of 5-FU and Vin in anthracycline and taxane pretreated patients with MBC...
  89. ncbi Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Gynecol Oncol 111:27-34. 2008
    ..We administered the combination of paclitaxel, topotecan and carboplatin to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity and to define its toxicity...
  90. ncbi Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
    George Pentheroudakis
    Ioannina University Hospital, Ioannina, Greece
    Acta Oncol 44:155-60. 2005
    ..Modern combination chemotherapy has satisfactory activity, with a minority of CUP patients enjoying long-term responses. Research efforts towards complete remission consolidation and molecular profiling are imperative...
  91. ncbi Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
    Dimosthenis V Skarlos
    Second Department of Medical Oncology, Henry Dunant Hospital, Athens, Greece
    Anticancer Res 25:3103-8. 2005
    ....
  92. ncbi Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial
    George A Plataniotis
    Department of Radiation Oncology, University of Thessalia, Thessalia, Greece
    Int J Radiat Oncol Biol Phys 59:1018-26. 2004
    ....
  93. ncbi Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group
    Efstathios S Papageorgiou
    Second Department of Internal Medicine, Athens University, University General Hospital Attikon, Haidari, Greece
    Eur J Haematol 75:124-9. 2005
    ..9 months. Toxicity was minimal and all patients were treated on an outpatient basis. The combination of gemcitabine and vinorelbine is an effective and well-tolerated regimen for patients with relapsed of refractory DLBL...
  94. ncbi Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study
    Helen Gogas
    University of Athens, Laikon Hospital, 11 527 Athens, Greece
    Anticancer Res 24:1947-52. 2004
    ..It has been suggested that the 1-month intravenous (i.v.) induction regimen may be sufficient to reduce the risk of relapse and death...
  95. ncbi Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study
    Aristotle Bamias
    Oncology Department, Ioannina University Hospital, Ioannina, Greece
    Am J Clin Oncol 27:465-71. 2004
    ..Objective response rate in 23 evaluable patients was 39.2%. The combination of LV5FU2 with bimonthly 90 mg/m2 cisplatin is feasible and active and should be further evaluated in patients with advanced gastric cancer...
  96. ncbi Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
    Paolo Bruzzi
    Unit of Clinical Epidemiology, National Institute for Cancer Research, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    J Clin Oncol 23:5117-25. 2005
    ..To assess the validity of objective response to chemotherapy as a surrogate end point for survival in metastatic breast cancer...
  97. ncbi Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)
    Jim Janinis
    Social Security Organization Oncology Center, Athens, Greece
    Anticancer Drugs 15:479-87. 2004
    ..The combination of paclitaxel with PLD demonstrated activity in recurrent or metastatic HNC, a favorable toxicity profile and relative ease of administration...
  98. ncbi Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials
    Issa J Dahabreh
    Department of Molecular Biology and Genetics, Metropolitan Hospital, 1, Ethnarhou Makariou and Venizelou Street, Piraeus, Greece
    Oncologist 13:620-30. 2008
    ..We performed a systematic review and meta-analysis to compare treatment outcomes for human epidermal growth factor receptor (HER)-2-positive breast cancer patients receiving adjuvant chemotherapy with or without trastuzumab...
  99. ncbi Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Gynecol Oncol 92:152-9. 2004
    ..We conducted a phase II study using the combination of carboplatin and gemcitabine for the treatment of patients with relapsed platinum-sensitive and paclitaxel-pretreated EOC...
  100. ncbi Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens
    Cancer Invest 26:491-8. 2008
    ..Toxicity was generally mild to moderate. Two cases of febrile neutropenia were reported. The E-CMF-T regimen is feasible and well tolerated...
  101. ncbi Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer
    Ralf Kurek
    Department of Radiotherapy, Klinikum Offenbach, Germany
    Strahlenther Onkol 179:292-7. 2003
    ..CONCLUSION: Knowledge of the initial tumor volume adds valuable information in terms of prognosis. Initial tumor volume should be included in all future clinical trials regarding head and neck cancer patients...